Publications

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma

Download PDF
Resource: ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma

.

Related Articles

Reversible Downregulation of HLA Class I in Adenoid Cystic Carcinoma

Link

Microfluidic-based immunohistochemistry combined with next-generation sequencing on diagnostic tissue sections for detection of tumoral BRAF V600E mutation

Link